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Serum protein induced by vitamin K absence or antagonist II (PIVKAII), hepatoma-specific band of serum gamma-glutamyl transferase
(GGTII), and a-fetoprotein (AFP) levels were determined in 120 patients with hepatocellular carcinoma (HCC) and 90 patients with
cirrhosis. The mean serum concentration of PIVKAII in HCC patients was higher than that in cirrhotic patients. A total of 53.3% of
patients (64 out of 120) with HCC had PIVKAII levels above 40mAUml
 1. However, only 13 patients with cirrhosis had higher
PIVKA II levels. Of 32 small HCC patients, 13 (40.6%) had PIVKAII values above 40mAUml
 1. An increased concentration of AFP
(i.e. 20ngml
 1) was observed in 70 out of 120 (58.3%) patients with HCC and in 33 out of 90 (36.7%) patients with cirrhosis.
Positive GGTII was found in 74.0% (89 out of 120) cases of HCC (sensitivity), in 16 of 90 cases of cirrhosis, and 14 of 32 (43.8%)
small HCC patients had GGTII positive. No significant correlation was found between serum levels of AFP and PIVKAII. Combining
the information from PIVKAII, AFP, and GGTII significantly increases the sensitivity over AFP alone. PIVKAII and GGTII are useful
tumour markers complementary to AFP for diagnosis of HCC.
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Hepatocellular carcinoma (HCC) is one of the most prevalent
causes of death in the world. As the majority of HCCs develop
from cirrhotic livers, particularly the posthepatitic or macronod-
ular variety, patients with cirrhosis are recommended to undergo
regular examinations for early detection of possible HCC (Okuda,
1986). Measurements of protein induced by vitamin K absence or
antagonist-II (PIVKAII) and a-fetoprotein (AFP) concentration,
along with several imaging modalities, have been used widely in
Japan and North America (Liebman et al, 1984; Okuda et al, 1987;
Fujiyama et al, 1988; Hattori et al, 1988). Although PIVKAII is a
tumour marker complementary to AFP for diagnosis of HCC, it
has not been used in China. We have determined PIVKAII levels in
60 patients with HCC and 30 patients with cirrhosis in China in
order to determine the usefulness of PIVKAII for diagnosing HCC
(Cui et al, 2002). We concluded that PIVKAII is a useful marker for
early diagnosis of HCC and may improve the sensitivity of
diagnosis when combined with AFP.
In 1984, Liebman et al first reported a specific increase of
plasma PIVKAII in HCC patients. Since then, an increasing
number of studies report that PIVKAII is a useful tumour marker
complementary to AFP in detecting HCC (Liebman et al, 1984;
Taketa et al, 1990; Sato et al, 1993). Serum PIVKAII has attracted
attention because of its very high specificity and lack of correlation
with serum AFP levels.
In 1965, Kokot and Kuska separated the serum gamma-glutamyl
transferase (EC 2.3.3.3, GGT) into three to four bands by means of
paper electrophoresis (Kokot and Kuska, 1965). Since then, other
methods have been used, that is, separation of GGT bands by
means of starch gel (Orlowski and Szczeklik, 1967), cellulose
acetate (Hitoi et al, 1984), agarose gel (Hetland et al, 1975),
polyacrylamide gel electrophoresis (Kojima et al, 1980; Suzuki et al,
1981; Sawabu et al, 1983; Kew et al, 1984), and polyacrylamide
stage gel plate (Xu et al, 1985). The polyacrylamide stage gel plate
method allows detecting positivity up to 90% in hepatoma patients
(Xu et al, 1985).
In this study, we have determined serum PIVKAII and GGTII
levels in patients with HCC or cirrhosis using ED036 kit and
polyacrylamide stage gel plate, respectively, in order to assess the
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clinical application.
MATERIALS AND METHODS
Patients
Serum PIVKAII and AFP levels and GGTII activity were
determined in 90 patients with cirrhosis and 120 patients with
HCC (their clinical characteristics are summarised in Table 1). In
patients with cirrhosis, HCC was ruled out on the basis of imaging
examinations including sonography and computed tomography
(CT) performed on a regular basis. Also, cirrhotic patients who
developed HCC within 1 year from getting serum were excluded. In
all, 58% (70 out of 120) of HCC patients were diagnosed by fine-
needle biopsy under the guidance of ultrasonography, and in 16%
(19), the diagnosis was confirmed after surgery. Ultrasonography,
CT, magnetic resonance imaging, and selective celiac angiography
diagnosed the remaining patients (26%, 31 out of 120). Computed
axial tomography (CAT) scan or celiac angiogram estimated the
two-dimensional size of the tumour included in this study. Medical
history, HBV and HCV infections, and liver functions (aspartate
transaminase (AST), alanine transaminase (ALT), GGT, alkaline
phosphatase, albumin and bilirubin levels of serum) were
recorded, and vitamin K and antibiotics were used. Patients with
vitamin K and antibiotic use in the recent 3 months, with a
hemoglobin levels under 490mgdl
 1 and free bilirubin concentra-
tions up to 27mgdl
 1 or conjugated bilirubin concentrations up to
22mgdl
 1 were excluded from this study. Venous blood samples
of the patients were obtained with a syringe containing a 3.8%
sodium citrate solution (9:1). The samples were immediately
centrifuged, and the serum was stored at  201C until the analysis.
Informed consent was obtained from each patient included in the
study. The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori approval by
the human research committee of Beijing Friendship Hospital.
Assay to determine serum PIVKAII concentrations
The serum PIVKAII concentrations were measured by the sensitive
enzyme immunoassay (EIA) (ED-036 kit, Eisai Laboratory, Tokyo,
Japan) according to the manufacturer’s instructions. The principle
of measurement is solid-phase, sandwich EIA. Briefly, using
solidified anti-PIVKAII monoclonal antibody, PIVKAII in the
specimen is allowed to react with enzyme-labelled antihuman
prothrombin antibody. When substrate solution is added to the
reaction product, the enzyme substrate in the substrate solution
decomposes, allowing the colouring agent to develop a colour. The
content of PIVKAII in the specimen is determined from
the absorption of the coloured solution. The cutoff value for the
sensitive EIA was set at 40mAUml
 1 according to the manufac-
turer’s instructions.
Serum GGTII
GGT activity assay was carried out on a vertical slab stage
polyacrylamide gel as described by Xu et al (1985). In brief, there
are three layers of separation gels: 15, 10, and 7.5% from the
bottom upward. The stacking polyacrylamide gel concentration is
4%. A measure of 20ml of serum mixed with an equal volume of
Laemmli buffer was loaded on the gel. After electrophoresis, the gel
plate was incubated at 371C for 60min with a substrate mixture
containing 0.82mmoll
 1 glutamyl-p-nitroanilide, 100mmoll
 1
tris, 100mmoll
 1 glycyl glycine, and 3.4mmoll
 1 N-(1-naphthyl)-
ethylenediamine dihydrochloride. Finally, the gel plate was
immersed in a solution containing 10g of trichloroacetic acid
and 25g of glycerol for every 100ml, and within a few minutes the
red bands corresponding to GGT appeared.
Serum AFP concentration
The serum concentration of AFP was determined by electro-
chemiluminescence immunoassay (Roche, Elecsys 1010/2010
Systems) according to the manufacturer’s instructions. The cutoff
level was fixed at 20ngml
 1.
Statistical analysis
Values are presented as mean 7s.d. The results were analysed
with the w
2 test, F-test, and Spearman’s test.
RESULTS
Serum levels of PIVKAII
The mean values of serum PIVKAII in 90 cirrhotic patients and 120
HCC patients were 18.4730.6 and 644.47146121mAUml
 1,
respectively. There was no significant difference between the mean
values of PIVKAII in male and female HCC or cirrhotic patients
(Po0.05). There was a statistically significant difference between
the mean values of PIVKAII in HCC patients and cirrhosis patients
(Po0.001).
In all, 13 out of 90 (14%) patients with cirrhosis, and 64 of 120
(53%) with HCC had PIVKAII levels above the detection limit of
40mAUml
 1. The overall accuracy, sensitivity, specificity, and
positive and negative predictive values for the usefulness in the
diagnosis of patients with HCC are given in Table 2. No correlation
was found between serum levels of PIVKAII and liver functions
(AST, ALT, GGT, alkaline phosphatase, albumin, and bilirubin
levels in serum, data not shown).
GGTII in patients with HCC and cirrhosis
Positive GGTII was found in 89 of 120 (74%) patients with HCC
and in 16 of 90 (18%) patients with cirrhosis. The overall accuracy,
sensitivity, specificity, and positive and negative predictive values
Table 1 Clinical Features of patients with HCC and cirrhosis in the
present study
Feature HCC Cirrhosis
Median age (years) (range) 59 (32–74) 56 (32–84)
Male/female ratio 2.7 2.1
Complication of cirrhosis 54.2% (65/120) 72.2% (65/90)
Positive for HBsAg 80.8% (97/120) 92.2% (83/90)
Positive for anti-HCV 0 1
Positive for both HBsAg and anti-HCV 0 0
Negative for both HBsAg and anti-HCV 17.5% (23/120) 8.9% (8/90)
HCC¼hepatocellular carcinoma; HBsAg¼hepatitis B surface antigen; anti-HCV¼
antibody to hepatitis C virus.
Table 2 Diagnostic values of PIVKAII for the detection of HCC
PIVKAII GGTII
Overall accuracy 67.1% ((64+77)/(90+120)) 77.6% ((89+74)/(90+120))
Sensitivity 53.3% (64/120) 74.2% (89/120)
Specificity 85.6% (77/90) 82.2% (74/90)
Positive predictive
value
83.1% (64/(64+13)) 84.8% (89/(89+16))
Negative predictive
value
57.9% (56/(56+77)) 70.5% (74/(31+74)
Overall accuracy¼(TP+TN)/(TP+FP+TN+FN); Sensitivity¼TP/(TP+FN); Specifici-
ty¼TN/(FP+TN); Positive predictive value¼TP/(TP+FP); Negative predictive
value¼TN/(FN+TN); TP¼true positive; TN¼true negative; FP¼false positive;
FN¼false negative.
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in Table 2. No correlation was found between serum GGTII and
liver functions (AST, ALT, GGT, alkaline phosphatase, albumin
and bilirubin levels of serum, data not shown).
Correlation between tumour size and PIVKAII level
The correlation of tumour size and PIVKAII level in 120 HCC cases
is shown in Figure 1. Overall, patients with bigger tumours tend to
have higher levels of PIVKAII.
Relation between serum levels of AFP, PIVKAII, and
positive GGTII
An AFP concentration above 20ngml
 1 was observed in 70 of 120
patients with HCC (58.3%) and in 33 of 90 patients with cirrhosis
(36.7%). The remaining 50 patients with HCC had AFP concentra-
tions of less than 20ngml
 1, and 24 of 50 patients (48.0%) had
elevated concentrations of PIVKAII. No significant correlation was
found between serum levels of AFP and PIVKAII in 120 HCC
patients (rs¼0.106, P¼0.249). Of 50 HCC patients, 31 (62.0%)
without increased AFP had been GGTII positive. No significant
correlation was found between serum levels of AFP and PIVKAII
in 120 HCC patients.
Combining the information on PIVKAII and AFP levels
significantly increases the sensitivity of diagnosis over AFP alone;
it showed an increase of approximately 20% above AFP alone and
25% above PIVKAII alone. Also, combining the information from
AFP levels and GGTII positive significantly increases the sensitivity
of diagnosis above AFP alone; it showed an increase of
approximately 25.9% above AFP alone and 10.2% above GGTII
alone. Combining the information from PIVKAII and AFP levels,
and GGTII positive significantly increases the sensitivity of
diagnosis above AFP alone; it showed an increase of approximately
29.2% above AFP alone, 34.2% above PIVKAII alone, and 13.5%
above GGTII alone (Table 3).
For HCC patients with tumours approximately less than 3cm in
dimension, combining the information from PIVKAII and AFP
levels significantly increases the sensitivity of diagnosis above AFP
alone also. It showed an increase of approximately 15.6% above
AFP alone and 18.8% above PIVKAII alone (Table 3). Combining
the information from PIVKAII and AFP levels, and GGTII positive
significantly increases the sensitivity of diagnosis above AFP alone;
it showed an increase of approximately 28.1% above AFP
alone, 31.3% above PIVKAII alone, and 28.1% above GGTII
alone (Table 3).
DISCUSSION
The diagnostic value of elevated AFP levels has been established,
but increased levels of AFP are also observed in acute and chronic
liver diseases as well as in other malignancies. Moreover, there are
false-negative results ranging between 10 and 50% depending on
ethnic and geographical variations and the techniques employed. It
is thus necessary to combine with markers for diagnosis of HCC in
a clinical setting. PIVKAII and GGTII are useful and early
diagnostic markers for HCC.
The amino-terminal glutamic acid residues of prothrombin
precursor undergo carboxylation in the liver, resulting in normal
prothrombin containing 10gamma-carboxy-glutamic acid resi-
dues. The absence of vitamin K or the presence of its antagonist
inhibiting the vitamin K-dependent carboxylase activity results in
the secretion of immature prothrombin into the blood that lacks
gamma-carboxy-glutamic acid residues (i.e. PIVKAII). Although
the precise mechanisms of PIVKAII production in HCC are not
fully understood, PIVKAII is now widely accepted as a tumour
marker for HCC in Japan (Ishii et al, 2000).
In 1984, Liebman et al measured abnormal prothrombin by a
competition radioimmunoassay using a conventional polyclonal
antibody in the serum of 76 HCC cases and reported increased
abnormal prothrombin in 69 (91%) cases; the level of these cases
exceeded 300ngml
 1 in 51 (67%) cases. They also described that
only three out of 28 cases (11%) with chronic active hepatitis
showed an increased abnormal prothrombin level. Together, the
assay for abnormal prothrombin and AFP identified 84% of 76
cases with HCC. Thus, they concluded that these two tests are
complementary tumour markers in this disease (Liebman et al,
1984). Since then, there have been many publications about the
usefulness of PIVKAII in the diagnosis of patients with HCC. The
sensitivity of PIVKAII in the diagnosis of patients with HCC had
been about 55% using a conventional kit (EI-test mono-P-II kit,
Eisai Laboratory) before 1998. Several studies on the contrasting
sensitivity kit and the conventional kit confirmed that the new kit
is more sensitive than the conventional one in diagnosing HCC
patients after 1998 (Mita et al, 1998; Nomura et al, 1999). The
sensitivity is about 65% in patients diagnosed with HCC (Mita et al,
1998). We measured the serum level of PIVKAII using the sensitive
kit in this study. There have been several publications about the
usefulness of PIVKAII in monitoring recurrence in patients with
HCC, as a prognostic marker in HCC, and as a marker of post-
transplant graft function (Nakao et al, 1995; Taketoshi et al, 1995;
Aoyagi et al, 1996; Suehiro et al, 1998).
In 1965, Kokot and Kuska separated the serum gamma-glutamyl
transferase (EC 2.3.3.3, GGT) into three to four bands by means of
paper electrophoresis (Kokot and Kuska, 1965). Other researchers
used polyacrylamide gel gradient electrophoresis to fractionate one
to three bands of GGT specific for hepatoma with a positivity rate
of only 27–63% (Hetland et al, 1975; Kojima et al, 1980; Sawabu
et al, 1983; Kew et al, 1984). In 1985, Xu reported that they had
fractionated nine to 11 activity bands of GGT adopting the method
of vertical slab stage electrophoresis on polyacrylamide gel (Xu
et al, 1985), in which GGTII was found in the sera of all patients
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Figure 1 Correlation between tumour size and PIVKAII level.
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Figure 2 Relation between PIVKAII and AFP levels in the 120 patients
with HCC.
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correlation was observed with AFP. After 10 years of follow-up,
they reported the following: (1) GGTII was positive in 90% of 90
cases with HCC and negative in most patients with acute and
chronic viral hepatitis, extrahepatic tumours, in pregnant women,
and in healthy controls. (2) The positive rate of GGTII assay was
higher than that of alkaline phosphatase isoenzyme I (ALP AFP,
and alpha 1-antitrypsin (AAT)) in 101 cases with HCC. In cases
where the AFP level was greater than 50ngml
 1 or less than
50ngml
 1, the positive rates of GGTII were 70.8 and 75–100%,
respectively. (3) Of the 14 cases of small-size HCC, the positive rate
of GGTII was 78.6%, which was higher than that of AFP (50%),
AAT (28.6%), and ALP I (0%). (4) Of the 62 cases that were false-
positive for the GGTII assay, 24.2% developed into HCC during a
follow-up of 2.1–20 months. Approximately 86.7% of subjects with
persistent positivity of GGTII and 22.2% of subjects with recurrent
positivity developed HCC. No patient with temporal positivity of
GGTII developed HCC (Xu et al, 1992). Yao modified the assay
procedure for the quantity detection of GGTII; however, its
sensitivity is less than the procedure without quantity detection
(Yao et al, 1998).
In this study, PIVKAII was proved to be useful for the diagnosis
of HCC in China. The sensitivity, specificity, and accuracy are
about 53.3, 85.6, and 67.1%, respectively, for all HCC patients.
These figures were similar to those in the study of Okuda et al
(1999) (45, 92.8, and 63.7%, respectively) but higher than those in
the study of Kuromatsu et al (1997) (27.9, 100, and 56.1%,
respectively). Most of the HCC patients in the Kuromatsu study
had tumours smaller than 3cm, whereas more than half of our
HCC patients had tumours larger than 3cm. The sensitivity is
about 40.6% for small-sized HCC patients. The figures were higher
than those in the study of Saitoh et al (1994) (24%, eight out of 34)
and lower than those in the study of Mita et al (1998) (71%, 12 out
of 17) because their criteria of small-sized HCC were different from
ours. GGTII was proved to be a useful tumour marker for HCC
diagnosis, although its sensitivity was less than that in Xu et al’s
reports (90%).
Measurement of AFP, PIVKAII, and GGTII may be more
advantageous than the measurement of only a single marker. In
fact, in the current cases with HCC development, AFP, PIVKAII,
and GGTII increase independently. The sensitivity of PIVKAII in
the HCC patients without increased AFP is about 48.0% in this
study. This figure was lower than the sensitivity in the study of
Mita et al (1998) (69%). In the study of Mita et al (1998), the
sensitivities of HCC, small-size HCC, and well-differentiated HCC
were also much higher than the sensitivities in the study of Saitoh
et al (1994) and our study. Okuda et al (1999), Kuromatsu et al
(1997), and Saitoh et al (1994) did not report the sensitivity of
PIVKAII in the HCC patients without increased AFP, so we are
unable to compare the senstivities. However, Saitoh et al (1994)
studied the correlation between AFP and PIVKAII measured by
the ABC method in patients with small-sized HCC and found no
apparent correlation. Kuromatsu and Okuda also detected no
obvious correlation between AFP and PIVKAII measured by the
revised EIA kit in their HCC patients (Kuromatsu et al, 1997;
Okuda et al, 1999). The sensitivity of GGTII in patients without
increased AFP was about 62%, which was less than that in Xu et al’s
(1985) report (84.6%). All papers about GGT in the HCC diagnosis
report no apparent correlation between AFP and GGTII, consistent
with the results of this study. Publications on the correlation
between GGTII and PIVKAII are not available. Our study showed
no apparent correlation between GGTII and PIVKAII. The
difference in the sensitivity of these two markers may be due to
different synthetic pathways in the cell. Thus, employing these
three complementary markers is useful in the diagnosis of
developing HCC, as shown in this study.
In conclusion, PIVKAII and GGTII are useful tumor markers
complementary to AFP for the diagnosis of HCC.
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